financetom
Business
financetom
/
Business
/
Tharimmune to Implement 1-for-15 Reverse Stock Split
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tharimmune to Implement 1-for-15 Reverse Stock Split
May 22, 2024 8:02 AM

10:38 AM EDT, 05/22/2024 (MT Newswires) -- Tharimmune ( THAR ) said Wednesday it will implement a 1-for-15 reverse stock split after the close of trading on Nasdaq on Friday.

The company said its shares will trade on a post-split basis under their current ticker symbol when the market opens on Tuesday.

The reverse stock split mainly aims to bring Tharimmune ( THAR ) into compliance with Nasdaq's $1 per share minimum bid price rule for continued listing, the company said.

Tharimmune ( THAR ) shares retreated by nearly 11% in recent trading.

Price: 0.35, Change: -0.04, Percent Change: -11.42

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Integrated Electrical Services Fiscal Q3 Adjusted Earnings, Revenue Climb; Board Approves $200 Million Buyback
Integrated Electrical Services Fiscal Q3 Adjusted Earnings, Revenue Climb; Board Approves $200 Million Buyback
Aug 2, 2024
08:42 AM EDT, 08/02/2024 (MT Newswires) -- Integrated Electrical Services (IESC) reported fiscal Q3 adjusted earnings Friday of $2.67 per diluted share, up from $1.08 a year earlier. Revenue for the quarter ended June 30 was $768.4 million, up from $584.4 million a year earlier. Analysts' estimates were not readily available for comparison. The company also said its board has...
ArcBest Q2 Non-GAAP Net Income Rises, Revenue Falls
ArcBest Q2 Non-GAAP Net Income Rises, Revenue Falls
Aug 2, 2024
08:39 AM EDT, 08/02/2024 (MT Newswires) -- ArcBest ( ARCB ) reported Q2 non-GAAP net income Friday of $1.98 per diluted share, up from $1.54 a year earlier. Analysts polled by Capital IQ expected $2.06. Revenue for the quarter ended June 30 was $1.08 billion, down from $1.10 billion a year earlier. Analysts surveyed by Capital IQ expected $1.06 billion....
Twist Bioscience Fiscal Q3 Loss Widens, Revenue Rises; Lifts Revenue Outlook for Fiscal Q4, 2024
Twist Bioscience Fiscal Q3 Loss Widens, Revenue Rises; Lifts Revenue Outlook for Fiscal Q4, 2024
Aug 2, 2024
08:36 AM EDT, 08/02/2024 (MT Newswires) -- Twist Bioscience ( TWST ) reported a fiscal Q3 loss Friday of $1.47 per diluted share, widening from a loss of $1.01 a year earlier. Analysts polled by Capital IQ expected a per-share loss of $0.77. Revenue for the quarter ended June 30 was $81.5 million, up from $63.7 million a year earlier....
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Aug 2, 2024
Thursday, the FDA approved Adaptimmune Therapeutics ( ADAP ) plc’s Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma, a rare type of cancer that tends to occur near large joints, mainly the knees. The approval covers patients who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. This indication is approved under...
Copyright 2023-2026 - www.financetom.com All Rights Reserved